Drug Detail:Sarilumab (Sarilumab [ sar-il-ue-mab ])
Drug Class: Antirheumatics Interleukin inhibitors
Sarilumab Levels and Effects while Breastfeeding
Summary of Use during Lactation
Because sarilumab is a large protein molecule with a molecular weight of about 150,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] One infant was safely breastfed for 6 months after maternal sarilumab was resumed at 28 days postpartum. If sarilumab is required by the mother, it is not a reason to discontinue breastfeeding.[2] Until more data become available, sarilumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
A woman with rheumatoid arthritis refractory to etanercept took sarilumab 200 mg every two weeks during pregnancy until 37 weeks of gestation. She was also taking prednisolone 10 mg and tacrolimus 3 mg daily. She delivered a healthy infant at 38 weeks of gestation and breastfed her infant. Prednisolone was continued postpartum, tacrolimus was restarted at 7 days postpartum and sarilumab was restarted at 28 days postpartum. The mother continued to breastfeed until 6 months postpartum. The infant was vaccinated with multiple live vaccines after reaching six months old, including the Bacille-Calmette-Guerin vaccine, with no adverse effects.[3]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Rheumatoid Arthritis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Tocilizumab
References
- 1.
-
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]
- 2.
-
Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810. [PubMed: 26888948]
- 3.
-
Mizutani S, Okunishi Y, Tamada T, et al. A woman with rheumatoid arthritis who successfully delivered a healthy child with continuous administration of sarilumab throughout pregnancy. Intern Med. 2023;62:633–6. [PMC free article: PMC10017234] [PubMed: 35871593]
Substance Identification
Substance Name
Sarilumab
CAS Registry Number
1189541-98-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal
Antirheumatic Agents
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification